Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.-论文-万方医学网

第一作者： Ezra Y,Rosen

第一单位： Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

作者： Ezra Y,Rosen ^[1] ; Melissa L,Johnson ^[2] ; Sarah E,Clifford ^[3] ; Romel,Somwar ^[4] ; Jennifer F,Kherani ^[5] ; Jieun,Son ^[3] ; Arrien A,Bertram ^[3] ; Monika A,Davare ^[6] ; Eric,Gladstone ^[4] ; Elena V,Ivanova ^[7] ; Dahlia N,Henry ^[5] ; Elaine M,Kelley ^[3] ; Mika,Lin ^[3] ; Marina S D,Milan ^[3] ; Binoj C,Nair ^[5] ; Elizabeth A,Olek ^[5] ; Jenna E,Scanlon ^[3] ; Morana,Vojnic ^[4] ; Kevin,Ebata ^[5] ; Jaclyn F,Hechtman ^[4] ; Bob T,Li ^[8] ; Lynette M,Sholl ^[9] ; Barry S,Taylor ^[10] ; Marc,Ladanyi ^[4] ; Pasi A,Jänne ^[3] ; S Michael,Rothenberg ^[5] ; Alexander,Drilon ^[11] ; Geoffrey R,Oxnard ^[3]

作者单位： Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ^[1] Department of Medicine, Sarah Cannon Cancer Center, Nashville, Tennessee. ^[2] Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[3] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. ^[4] Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut. ^[5] Oregon Health and Science University, Portland, Oregon. ^[6] Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[7] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.;Weill Cornell Medical College, New York, New York. ^[8] Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. ^[9] Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. ^[10] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. drilona@mskcc.org.;Weill Cornell Medical College, New York, New York. ^[11]

医学主题词成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);临床试验, Ⅰ期(主题)(Clinical Trials, Phase I as Topic);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);基因扩增(Gene Amplification);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);癌基因蛋白质类, 融合(Oncogene Proteins, Fusion);试点项目(Pilot Projects);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-met(Proto-Oncogene Proteins c-met);原癌基因蛋白质c-ret(Proto-Oncogene Proteins c-ret);吡唑类(Pyrazoles);吡啶类(Pyridines);治疗结果(Treatment Outcome)

DOI 10.1158/1078-0432.CCR-20-2278

PMID 33082208

发布时间 2022-10-05

检索历史清除

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.

Clinical cancer research

相似文献

同项目论文

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.

Clinical cancer research

相似文献

同项目论文

Clinical cancer research

相关期刊

检索历史清除